KBL Merger Corp. IV (KBLM), released details this morning on their previously announced non-binding term sheet ahead of their June 5th extension vote. KBLM’s LOI with with CannBioRx Life Sciences Corp. (“CannBioRx”), would form a company combined of three programs focused on treating inflammatory diseases:
- 180 Therapeutics, a late clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic therapies for treating fibrosis;
- Katexco Pharmaceuticals, a pre-clinical effort for developing orally available therapies harnessing the brain’s nicotinic receptors to treat inflammatory diseases; and
- CannBioRexPharmaceuticals, a pre-clinical initiative focused on the development and commercialization of man-made cannabinoids for arthritis, pain, diabetes and obesity.
Important to note, KBL states these opportunities are non-plant-touching, pharmaceutical-grade, non-psychoactive cannabis and drug development programs.
Shareholder Vote to Extend: To be held June 5th, record date is May 15th
No further details on the transaction have been released as of yet, but it is important to note that KBLM will be changing it’s previous extension amendment. Per the first extension amendment, KBLM had previously agreed to contribute $0.03 for each public share that was not redeemed for each calendar month commencing on June 7, 2019, through September 7, 2019 (should they need the full three months). However, KBLM is now asking for a potential six months, which would move their potential deadline date to December 7th instead. Additionally, instead of $0.03 per share per month, KBLM will now be contributing $0.025 per share per month, for a total of $0.15 per share should they need the full six months.
Quick Takes: While cannabis companies are hot, we still do not have a lot of details on this transaction. However, two out of the three of CannBioRx’s programs are at the pre-clincial stage. It’s difficult to evaluate the opportunity without specifics, but clearly this was announced ahead of the extension vote to give shareholders something to chew on before they decide to redeem or not. However, reducing the per month contribution from $0.03 to $0.025 might be detrimental. A longer duration and a reduced monthly contribution are generally not well received by SPAC investors.
Terms Tracker for the Week Ending May 30, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. May went out with a bang. Four more IPOs priced this week, bringing the monthly tally to 22 and the YTD total to 53. That...
June is set to be one of the quietest months in some time in terms of sponsors and de-SPAC’d companies coming free from their lock-ups, owing to the quieter periods for transactions closing that occurred six and 12 months ago. Up first will be company shareholders for East Asian media conglomerate TNL Mediagene (NASDAQ:TNMG) on...
Pioneer I (NASDAQ:PACHU) has filed for a $220 million SPAC to hunt for a healthcare target with a mix of industry veterans heading up its team. The new SPAC is the 12th new S-1 underwritten by Cantor Fitzgerald this year as left lead as it hopes to join the 10 SPACs that the underwriter has...
At the SPAC of Dawn This week comes to an end with a flurry of SPAC votes including three special meetings called for shareholders to approve business combinations. Aetherium (OTC:GMFI) was also scheduled to seek shareholder approval for its extension proposal, but has punted this vote for two weeks to June 13. Two of today’s...
At the SPAC of Dawn After multiple days of market rallies, traders are set to ingest a full plate of economic indicators today with jobless claims coming first, followed by a GDP growth revisions, home sales and a raft of Fed comments. GDP figures for the first quarter are broadly forecast to be revised downward...